Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 281500
Licensor discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.
IPSCIO Record ID: 341530
Inflammatory Bowel Disease (IBD) This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel.
Crohnâ€™s disease (CD) An IBD involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel.
Ulcerative colitis (UC) An IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract).
Rheumatoid arthritis (RA) A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability.
Inflammatory diseases is a large, unrelated group of disorders associated with abnormalities in inflammation.
IPSCIO Record ID: 260445
With the First Amendment to the License Agreement under which Licensee granted to Licensor the right to co-market the Product containing the oral form of Enoximone (Oral Enoximone) in Europe. This grant was terminated under the Second Amendment to the License Agreement.
The Second Amendment provided for a certain royalty to be paid by Licensee to Licensor in the event the Net Sales of Oral Enoximone in Europe reached or exceeded the threshold set forth in the amendment.
Licensor was acquired by a pharmaceutical company organized under the laws of France.
The Parties acknowledge and agree that the License Agreement only obligates Licensee to pay Licensor royalties on Net Sales of Perfan i.v. in the Limited European Countries. The Agreement does not obligate Licensee to pay royalties on the Net Sales of Oral Enoximone in the Limited European Countries. The Parties further acknowledge and agree that the License Agreement, as amended and restated, only concerns and relates to the sale of any Product, including Perfan i.v. and Oral Enoximone, in any Territory other than Europe, and only concerns and relates to the sale of any Additional Product in the Limited European Countries.
Licensor transfer of the Licensor Trademarks in the United Kingdom and the Benelux countries of Belgium, the Netherlands and Luxembourg, is perpetual and irrevocable, as of the Effective Date of the Third Amendment.
PerfanÂ® I.V. is an intravenous (i.v.) formulation of enoximone.